Global Biosimilars WeekGlobal Biosimilars Week

  • About
  • Basics
  • Approvals
  • Benefits
  • Experience
  • Future
  • Social Media
  • Resources

Global Biosimilars Week

MENU

Press Enter To Begin Your Search

PORTFOLIO Reports

  • Biosimilars in the EU

    Biosimilars in the EU

    Reports

  • The impact of the biosimilars competition’ (2019)

    The impact of the biosimilars competition’ (2019)

    Reports

  • White Paper: Breaking Through on Biosimilars

    White Paper: Breaking Through on Biosimilars

    Reports

  • What you Need to Know about Biosimilar Medicinal Products

    What you Need to Know about Biosimilar Medicinal Products

    Reports

  • Biologics in Canada, 2018

    Biologics in Canada, 2018

    Reports

  • A recommended Reading List on biosimilar medicines (2019)

    A recommended Reading List on biosimilar medicines (2019)

    Reports

  • Advancing Biosimilar Sustainability in Europe (2018)

    Advancing Biosimilar Sustainability in Europe (2018)

    Reports

  • Delivering on the potential of biosimilar medicines’ (2016)

    Delivering on the potential of biosimilar medicines’ (2016)

    Reports

  • Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada

    Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada

    Reports

  • 1
  • 2
  • →
CONTACT US
IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION
C/O DYN SA - Rue de Cornavin 11 - 1201 Geneva, Switzerland - Telephone: +32 (0)2 5346607 (S. Kox)
E-mails: info@igbamedicines.org / skox@igbamedicines.org (Secretary General)
© 2020 International Generic and Biosimilar Medicines Association (IGBA), All Rights Reserved. For more information, contact IGBA